Andrew Kruegel is a medicinal chemist and pharmacologist who has focused on drug design and preclinical development for psychiatric treatment. He has also developed expertise in business operations, fundraising, and intellectual property strategy.
Intro paths
YC
Andrew went through Y Combinator (Summer 2020) — any YC alum in your network can reach them through the YC community.
GP
Their group partner at YC was Jared Friedman, General Partner at Y Combinator — the partner who ran Gilgamesh Pharmaceuticals's batch and knows the company first-hand. YC profile ↗
→
In turn, Andrew can intro founders to Gilgamesh Pharmaceuticals's investors below.
Gilgamesh Pharmaceuticals's investors · 10
Co-founders
JS
Jonathan SpornFounder
DS
Dalibor SamesFounder
JS
JONATHAN SPORNFounder
TK
Thomas Kevin Murphy, Ph.D.Executive Officer
AK
Andrew Kruegel, Ph.D.Executive Officer
JS
Jonathan Sporn, M.D.President and Chief Executive Officer